| Seropositive | Seronegative | p-level |
---|---|---|---|
ON at onset | Â | Â | Â |
   Total cohort | 61/135 (45.2%) | 14/38 (36.8%) | n.s.‡ |
Patients meeting Wingerchuk's 2006 criteria | 56/90 (62.2%) | 12/27 (44.4%) | n.s.‡ |
MY at onset | Â | Â | Â |
   Total cohort | 64/135 (47.4%) | 14/38 (36.8%) | n.s.‡ |
Patients meeting Wingerchuk's 2006 criteria | 24/90 (26.7%) | 5/27 (18.5%) | n.s.‡ |
BSTE at onset | Â | Â | Â |
   Total cohort | 4/135 (3%) | 1/38 (2.6%) | n.s.‡ |
Patients meeting Wingerchuk's 2006 criteria | 4/90 (4.4%) | 1/27 (3.7%) | n.s.‡ |
Simultaneous MY and ON at onset | Â | Â | Â |
   Total cohort | 6/135 (4.4%) | 9/38 (23.7%) | p < 0.001‡ |
Patients meeting Wingerchuk's 2006 criteria | 6/90 (6.7%) | 9/27 (33.3%) | p < 0.013‡ |
Bilateral ON at onset | Â | Â | Â |
   All patients with a history of ON | 9/63 (14.3%) | 9/22 (40.9%) | p < 0.015‡ |
Patients meeting Wingerchuk's 2006 criteria | 9/59 (15.3%) | 8/20 (40%) | p < 0.029‡ |